FILIP1LΔC103 (COOH terminal truncation mutant 1-790 of
Filamin A Interacting
Protein 1-Like) has been identified to hold therapeutic potential for suppressing
tumor growth.
Cisplatin (DDP) is commonly used as a first-line drug in the treatment for
ovarian cancer. The usage of polymeric nanoparticles to deliver functional genes intraperitoneally holds much promise as an effective
therapy for
ovarian cancer. In this study, a recombinant plasmid expressing FILIP1LΔC103 (FILIP1LΔC103-p) was constructed, and HPEI
nanogels were prepared to deliver FILIP1LΔC103-p into SKOV3 cells. The expression of FILIP1LΔC103 in vitro and in vivo was determined using RT-PCR and Western Blotting. Moreover, in vivo treatment experiments were conducted on nude mice bearing SKOV3
ovarian cancer. The mice were treated with 5%
glucose, HPEI+E-p, HPEI+FILIP1LΔC103-p, DDP or HPEI+FILIP1LΔC103-p plus DDP, respectively.
Tumor weights were evaluated throughout the
treatment duration. The cell proliferation and apoptosis were evaluated by Ki-67 immunochemical staining and TUNEL assay respectively, and the anti-angiogenic effect was assessed by CD31 immunochemical staining and
alginate-encapsulated
tumor cell assay. FILIP1LΔC103-p could be efficiently transfected into SKOV3 cells by HPEI
nanogels. The combination of HPEI+FILIP1LΔC103-p with DDP exerted enhanced antitumor activity compared with HPEI+FILIP1LΔC103-p or DDP alone. Significant reduction of
tumor cells proliferation, augmentation of
tumor cells apoptosis and suppression of angiogenesis were observed in the combination group compared with controls. Our results demonstrated synergistic
antineoplastic activity of combined FILIP1LΔC103 and low-dose DDP with no apparent toxicity, indicating a potential application of the combined approach in the treatment of
ovarian cancer.